New Treatment Options for Relapsed/Recurrent DLBCL: Impact on Sequencing Therapeutic Choices : Episode 16

Opinion

Video

August 19, 2024

Disparities in access to newer or expensive treatments, unmet needs in the treatment of DLBCL

Author(s):

Matthew A. Lunning, DO, FACP, University of Nebraska Medical Center,Elizabeth Budde, MD, PhD

A panel of experts discuss the current treatment landscape for bispecific antibodies and CAR T in R/R DLBCL.

EP: 1.Navigating Second-Line Treatments and CAR T-Cell Therapy for DLBCL: Insights from Dr. Budde and Dr. Lunning

EP: 2.Dr Locke, Dr Hunter, Dr Lunning Share Referral Patterns in Their Practices

EP: 3.Dr Locke Shares Key Takeaways from ZUMA-7 and TRANSFORM Studies

EP: 4.Dr Gordon Shares Key Takeaways from ALYCANTE and PILOT for 2L CAR T-cell Transplant-Ineligible Population

EP: 5.Dr Hunter Shares Key Takeaways from L-MIND 5-Year Data and RE-MIND2 Study

EP: 6.Panel Discuses Use of CD19 Bispecifics in Sequencing

EP: 7.Panel Discusses Challenges with CAR T Therapy in R/R DLBCL, Particularly Around T-cell Exhaustion

EP: 8.Current Approach to Bridging Therapy in R/R DLBCL

EP: 9.Risk of Secondary Malignancies in Heavily Pre-Treated Population

EP: 10.Management of CRS and ICANS with CAR T-cell Therapy

EP: 11.Third-line Treatment Options for DLBCL After CAR T-cell Therapy or ASCT in Second-line

EP: 12.Contemporary Sequencing CD20xCD3 Bispecific Antibody R/R DLBCL Who Have progressed beyond CAR T-cell therapy

EP: 13.Bispecific therapy – treatment setting and management of short-term adverse events

EP: 14.Bispecific therapy – management of long-term adverse events in the community setting

EP: 15.Practice Patterns and Real Use of Epcoritamab and Glofitamab

EP: 16.Disparities in access to newer or expensive treatments, unmet needs in the treatment of DLBCL

Video content above is prompted by the following:

What are your thoughts on the current treatment landscape for bispecific antibodies and CAR T in R/R DLBCL, specifically related to sequencing and transplant eligibility?

Related Videos

Related Content

Related Content

Latest Conference Coverage

Active Monitoring Is Noninferior to Guideline Concordant Care in Low-Risk DCIS

Postoperative Radiation Therapy Improves HRQOL, Safety in Early-Stage HR+/HER2– Breast Cancer

Baseline ctDNA Is Associated With Larger Pathological Tumors in HR+ Early Breast Cancer

Elacestrant Improves Real-World Time to Next Treatment or Treatment Discontinuation in ESR1+ HR+/HER2– Breast Cancer

View More Latest Conference Coverage

Editorial Board

MJH Life Sciences brands

Terms & Conditions

Do Not Sell My Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2024 MJH Life Sciences

All rights reserved.